Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dry eye eye-drop comparison study
ACTRN12621001737820Phase 4Completed
- Sponsor
- University of New South Wales
- Start
- Apr 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Systane HYDRATION, hyaluronic acid sodium salt and sodium chloride in dry eye syndrome (DED) (3 arms), sponsored by University of New South Wales. Primary endpoints: Change in corneal epithelial irregularity factor and Corneal epithelial irregularity factor. Started Apr 2022; status: completed.
02
Drugs
Systane HYDRATIONhyaluronic acid sodium saltsodium chloride
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on ACTRN12621001737820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001737820.